| Date |
Press Releases |
Link to PDF File |
| May. 12, 2009 |
NeurAxon, Inc. Announces Two Presentations at BIO International Convention May 19, 2009 |
|
| Mar. 27, 2009 |
NeurAxon, Inc. to Present at the BIO National Venture Conference April 1, 2009 |
|
| Nov. 18, 2008 |
NeurAxon, Inc. to Present at 20th Annual Piper Jaffray Health Care Conference December 2, 2008 |
|
| Oct. 27, 2008 |
NeurAxon's NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover |
|
| Oct. 23, 2008 |
NeurAxon, Inc. to Present at the BIO Investor Forum October 30, 2008 |
|
| Oct. 16, 2008 |
NeurAxon, Inc. to Present at First Annual Boston Biotech R&D Conference October 22, 2008 |
|
| Sept. 16, 2008 |
NeurAxon Appoints Thomas Lategan, PhD as Vice President of Regulatory Affairs |
|
| Sept. 5, 2008 |
NeurAxon’s NXN-188 Demonstrates Pain Relief in Migraine with Aura |
|
| June 17, 2008 |
NeurAxon, Inc. to Present at BIO International Convention June 18, 2008 |
|
| Mar. 25, 2008 |
NeurAxon, Inc. to Present at the BioCentury Future Leaders
Conference March 27, 2008
|
|
| Mar. 11, 2008 |
NeurAxon Announces the Appointment of David Brand
to Its Board of Directors |
|
| Feb. 7, 2008 |
NeurAxon, Inc. to Present at 10th Annual BIO CEO & Investor Conference |
|
| Jan. 4, 2008 |
NeurAxon, Inc. to Present at 26th Annual JPMorgan Healthcare Conference January 10, 2008 |
|
| Aug. 20, 2007 |
NeurAxon Announces $32 Million Series B Financing |
|
| Aug. 14, 2007 |
NeurAxon Announces Positive Phase 1 Trial Data on NXN-188 for Migraine |
|
| Aug. 7, 2007 |
NeurAxon Appoints Robert Medve, MD, as Chief Medical and Regulatory Officer |
|
| July 31, 2007 |
NeurAxon Appoints Lawrence E. Bloch, MD, JD, as Chief Executive Officer |
|
|
